Physician profile
Anthony Jack Pick
NPI 1942373527
$664,840.10
in general payments reported to CMS, 2019-2025
27 companies · $124K in 2025
The $124K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90K · 2020: $40K · 2021: $57K · 2022: $124K · 2023: $84K · 2024: $146K · 2025: $124K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $246K · Travel and Lodging: $31K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $30K · Consulting Fee: $23K · Food and Beverage: $13K · Honoraria: $8,940 · Education: $1,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $246,080.50 |
| Travel and Lodging | $31,288.68 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $30,468.00 |
| Consulting Fee | $22,835.50 |
| Food and Beverage | $12,691.54 |
| Honoraria | $8,940.00 |
| Education | $1,539.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $217,747.80 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $149,800.91 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $56,156.23 | 2021-2025 | |
| Abbott Laboratories | $50,899.77 | 2020-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45,642.66 | 2019-2025 | Jardiance, Synjardy |
| Madrigal Pharmaceuticals | $41,563.32 | 2024-2025 | Rezdiffra, Resmetirom |
| Sanofi-Aventis U.S. LLC | $31,424.98 | 2023-2025 | |
| Dexcom, INC. | $22,956.05 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $15,607.95 | 2019-2023 | Farxiga |
| Xeris Pharmaceuticals, INC. | $10,406.53 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Ascensia Diabetes Care US INC. | $8,397.99 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $6,574.38 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $3,455.76 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Eli Lilly and Company | $2,600.00 | 2020 | |
| Amgen INC. | $657.96 | 2019-2025 | Evenity, Repatha, Tepezza |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $176.62 | 2022-2023 | Omnipod |
| Radius Health, INC. | $158.35 | 2019-2025 | Tymlos |
| Mannkind Corporation | $136.52 | 2021-2025 | |
| Companion Medical, INC. | $128.91 | 2019-2020 | |
| Glaxosmithkline, LLC. | $83.38 | 2022 | |
| Corcept Therapeutics | $62.94 | 2025 | Korlym |
| Ucb, INC. | $60.94 | 2021 | |
| Ascendis Pharma Endocrinology INC | $48.89 | 2025 | Yorvipath |
| Amarin Pharma, INC. | $42.25 | 2019 | |
| Vivus LLC | $18.08 | 2024 | Qsymia |
| Axsome Therapeutics, INC. | $17.49 | 2025 | Auvelity |
| Antares Pharma, INC. | $13.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Pick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.